Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.64 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167426 | 0.88 | CFTR (0.71) | CFTRCES2TAS2R14SORT1NOTUM | |
| SCHEMBL8613343 | 0.86 | CFTR (0.53) | CFTRCES2TAS2R14SORT1MCL1 | |
| SCHEMBL22263091 | 0.86 | CFTR (0.73) | CFTRCES2SORT1NOTUMMRGPRX4 | |
| SCHEMBL13206086 | 0.84 | KIF11 (0.48) | CFTRKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL10566215 | 0.83 | MRGPRX4 (0.49) | CFTRCES2MRGPRX4KDM4EALDH1A1 | |
| SCHEMBL1679303 | 0.83 | RXRA (0.49) | CFTRCES2TAS2R14SORT1KDM4E | |
| SCHEMBL1995951 | 0.83 | CES2 (0.71) | CFTRCES2NOTUMMRGPRX4KDM4E | |
| SCHEMBL284138 | 0.83 | CFTR (0.64) | CFTRCES2NOTUMMRGPRX4KDM4E | |
| SCHEMBL13280707 | 0.83 | CFTR (0.64) | CFTRCES2NOTUMMRGPRX4 | |
| SCHEMBL10742959 | 0.83 | CFTR (0.64) | CFTRCES2SORT1NOTUMMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| CN-119751411-A | Aggregation-induced emission probe design, synthesis and sterilization application based on bioorthogonal reaction metabolism anchoring living bacteria strategy | 华南农业大学 | 2025-04-04 | — | — | CN | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10479779-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-10479778-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20170253579-A1 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-09-07 | — | — | US | disclosed |
| US-9688661-B2 | Substituted pyrroles active as kinases inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-27 | — | — | US | disclosed |
| US-20150166512-A1 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-06-18 | — | — | US | disclosed |
| EP-2880025-A2 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2015-06-10 | — | — | EP | disclosed |
| CN-104507923-A | Substituted pyrrole active agents as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2015-04-08 | — | — | CN | disclosed |
| WO-2014019908-A2 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-06 | — | — | WO | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| CN-1064955-C | Fluorine-containing benzoylguanidines | MERCK PATENT GMBH (DE) | 2001-04-25 | — | — | CN | disclosed |
| CN-1143632-A | Fluorine-containing benzoylguanidines | MERCK PATENT GMBH (DE) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166512-A1 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | JAK2, JAK1, JAK3 | CFTR 2594/4885CES2 3850/4885TAS2R14 4552/4885 |
| US-20170253579-A1 | SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | JAK2, JAK1, JAK3 | CFTR 2594/4885CES2 3850/4885TAS2R14 4552/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | CFTR 670/4885CES2 1667/4885TAS2R14 4463/4885 |
| US-10479779-B2 | Substituted pyrroles active as kinases inhibitors | JAK2, JAK1, JAK3 | CFTR 2594/4885CES2 3850/4885TAS2R14 4552/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CFTR 4669/4885CES2 1414/4885TAS2R14 4592/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | CFTR 670/4885CES2 1667/4885TAS2R14 4463/4885 |
| US-10479778-B2 | Substituted pyrroles active as kinases inhibitors | JAK2, JAK1, JAK3 | CFTR 2594/4885CES2 3850/4885TAS2R14 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.